PMID- 38318261
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240207
IS  - 8755-1225 (Print)
IS  - 1549-4810 (Electronic)
IS  - 1549-4810 (Linking)
VI  - 40
IP  - 1
DP  - 2024 Feb
TI  - Evaluation of Gabapentin and Pregabalin Use in Hospitalized Patients With 
      Decreased Kidney Function.
PG  - 30-36
LID - 10.1177/87551225231217906 [doi]
AB  - Background: Gabapentin and pregabalin are well-tolerated medications primarily 
      cleared by the kidney. Patients receiving higher gabapentinoid doses with 
      decreased kidney function may be at an increased risk of adverse effects (AEs), 
      but limited evidence exists evaluating gabapentinoid dosing and AEs in this 
      population. Objective: To determine whether patients with decreased creatinine 
      clearance (CrCl) experienced increased frequency of AEs related to gabapentinoid 
      dose at hospital admission. Methods: Single-center retrospective cohort study in 
      adults with a gabapentinoid prescription and serum creatinine measurement 
      documented on hospital admission. The primary outcome was the appropriateness of 
      gabapentinoid prescription based on CrCl (stratified by CrCl >/=60 mL/min, <60 
      mL/min, 15-29 mL/min, and <15 mL/min) at admission. Secondary outcomes included 
      the incidence of AEs related to gabapentinoids and concomitant opioid and 
      psychiatric prescriptions. Results: A total of 286 patients were included in this 
      study (gabapentin n = 234, pregabalin n = 52). Patients with a CrCl <60 mL/min 
      and doses above the manufacturer's recommendation were prescribed gabapentin 
      (34%) and pregabalin (22.7%). For patients with a CrCl of 15 to 29 mL/min and <15 
      mL/min groups, inappropriately high doses were prescribed for gabapentin (48.8%) 
      and pregabalin (45%). A significant increase in recorded falls (P = 0.029) was 
      identified in patients with a CrCl <60 mL/min. Concomitant opioid and psychiatric 
      medications contributed to a higher prevalence of AEs regardless of CrCl. 
      Conclusions: Patients with a CrCl <60 mL/min were frequently prescribed 
      inappropriately high doses of gabapentinoids. The relationship between 
      gabapentinoid dosing, kidney function, and the incidence of gabapentinoid-related 
      AEs at hospital admission requires larger, multicentre studies.
CI  - (c) The Author(s) 2023.
FAU - Knowles, Gwendolyn M
AU  - Knowles GM
AD  - Department of Pharmacy Practice and Administration, University of Maryland 
      Eastern Shore School of Pharmacy, Princess Anne, MD, USA.
FAU - LaFleur, Grace E
AU  - LaFleur GE
AUID- ORCID: 0000-0001-7216-1354
AD  - Department of Pharmacotherapy, College of Pharmacy, University of Utah, Salt Lake 
      City, UT, USA.
FAU - Churchwell, Mariann D
AU  - Churchwell MD
AUID- ORCID: 0000-0001-5866-0456
AD  - Department of Pharmacy Practice, College of Pharmacy and Pharmaceutical Sciences, 
      The University of Toledo, Toledo, OH, USA.
LA  - eng
PT  - Journal Article
DEP - 20231218
PL  - United States
TA  - J Pharm Technol
JT  - The Journal of pharmacy technology : jPT : official publication of the 
      Association of Pharmacy Technicians
JID - 8504643
PMC - PMC10838538
OTO - NOTNLM
OT  - adverse effects
OT  - gabapentin
OT  - gabapentinoid
OT  - kidney function
OT  - pregabalin
COIS- The author(s) declared no potential conflicts of interest with respect to the 
      research, authorship, and/or publication of this article.
EDAT- 2024/02/06 06:42
MHDA- 2024/02/06 06:43
PMCR- 2024/12/18
CRDT- 2024/02/06 03:56
PHST- 2024/12/18 00:00 [pmc-release]
PHST- 2024/02/06 06:43 [medline]
PHST- 2024/02/06 06:42 [pubmed]
PHST- 2024/02/06 03:56 [entrez]
AID - 10.1177_87551225231217906 [pii]
AID - 10.1177/87551225231217906 [doi]
PST - ppublish
SO  - J Pharm Technol. 2024 Feb;40(1):30-36. doi: 10.1177/87551225231217906. Epub 2023 
      Dec 18.